• Readly

  Led · Equity · Jun 2019

  Readly is a digital magazine subscription service founded in 2012 in Växjö, Sweden. The company offers users unlimited access to over 4,000 local and international magazine titles through one app. It operates in eight European countries and the US and generates more than two-thirds of its revenues outside its Swedish headquarters. Readly plans to continue expanding across European markets and to lead the digital transformation of magazine publishing, according to CEO Maria Hedengren. The company was ranked in the Financial Times’ 2019 ‘1000 Fastest Growing Companies in Europe’ (top 200 overall and the second fastest growing company in Sweden). In May 2019 Readly launched its service in Italy, further strengthening its content portfolio. Readly is a Stockholm-based digital magazine newsstand that offers a subscription app for tablets and mobile phones. Led by CEO Jörgen Gullbrandson, the app gives customers access to national and international magazines for a monthly fee. The service has readers in 46 markets and provides access to over 3,200 national and international digital magazines. Readly is present in Sweden, the UK, Germany, Austria and Switzerland and plans further international expansion. In August 2018 the company raised €10m in funding, with backers including Swedbank Robur and Zouk Capital. The company intends to use the funds to continue expanding internationally and to grow in its existing markets. Readly is a subscription service often described as the "Spotify for magazines," offering users access to a large selection of magazines for a fixed monthly fee. The company underwent a major overhaul in 2015 and refocused on core markets including Sweden, England and Germany. After experiencing financial difficulties, Readly is now reporting a recovery and has secured new financing. Management says the service converts about 30% of users into paying customers after the test period. The recent fundraise provides fresh capital as the company continues to execute on its core-market strategy. No revenue figures or founding year are disclosed in the article.

• BONESUPPORT

  Participated · Equity · Oct 2016

  Bonesupport develops Cerament, a radiopaque injectable osteoconductive bioceramic platform that remodels to host bone over six to twelve months and treats bone voids from trauma, infection, disease, or surgery. Its lead product, Cerament BVF, aims to avoid hospital readmissions and revision surgery caused by failed bone healing and residual bone voids. The company also offers CE‑marked antibiotic‑eluting variants, Cerament G and Cerament V, which provide local high initial antibiotic concentrations followed by sustained dosing above MIC. Cerament products are commercially available in the U.S., EU, SE Asia and the Middle East. Bonesupport recently received FDA approval to begin an IDE study with Cerament G, with the first patient expected before the end of 2016. The company intends to use new funds to drive Cerament sales in existing and new markets, generate further clinical data, and continue building its product pipeline. Bonesupport develops and sells Cerament, an injectable synthetic bone substitute used in orthopedic trauma, bone infections and instrument augmentation. Cerament is clinically shown to remodel into bone within 6–12 months. The CERAMENT™|G formulation is the first CE-marked injectable gentamicin antibiotic‑eluting ceramic bone graft substitute and is indicated for managing osteomyelitis in CE-marked countries (it is not available in the United States). Founded in 1999 by Lloyd Diamond and Oern R. Stuge, the company is headquartered in Lund, Sweden and has subsidiaries in the US and Germany. Bonesupport intends to use the funds to grow global sales and marketing and to accelerate expansion of the CERAMENT platform. The article reports the company closed a $14M financing in April 2015. BONESUPPORT develops injectable bone substitutes, with its CERAMENT™ platform commercially available in the U.S. and Europe for treatment of fragility and other fractures. The company focuses on orthopedic trauma, bone infection, instrument augmentation related to orthopedic surgery and spinal applications. It intends to use newly raised capital to accelerate commercial expansion in the US, Europe and Asia and to support the upcoming launch of an antibiotic‑formulated CERAMENT. BONESUPPORT also plans to further drive research and development and widen its product offerings. The company was founded in 1999 and is led by CEO Lloyd Diamond and Executive Chairman Oern Stuge, and it has subsidiaries in the US and Germany. Financially, it completed a second and final tranche of financing after having raised approximately SEK101m in 2011. BONESUPPORT develops CERAMENT, a ceramic‑like, non‑toxic, tissue‑friendly material that remodels into bone and is used to heal vertebral compression fractures and reinforce osteoporotic femoral necks. The company is pursuing ongoing product development including prophylaxis of hip fractures and combinations with antibiotics for prophylaxis or treatment of orthopedic infections. It intends to use the new funding to continue expanding and further developing its pipeline of products. BONESUPPORT was founded in 1999 by CEO Lars Lidgren and is headquartered at Ideon Science Park in Lund, Sweden. The company has over 30 employees and maintains subsidiaries in the United States, the Netherlands and Germany. The article reports the recent SEK120m raise to support these development and expansion plans.

No current team members are available.